Arranon FDA Approval History
FDA Approved: Yes (First approved October 28, 2005)
Brand name: Arranon
Generic name: nelarabine
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Acute Lymphoblastic Leukemia, Lymphoma
Arranon (nelarabine) is a chemotherapy agent indicated for the treatment of adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
Development timeline for Arranon
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
